ARIBIO Holdings Inc.
KKRX:2906902,810.00
KRW
-135.00
(-4.58%)
ISIN
KR7290690007
Return %
Stock
S&P 500
1Y
-32.78
14.20
3Y
-49.40
81.12
5Y
-26.05
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Jae-Joon Jeong
- Full Time Employees
- 109
- Sector
- Producer manufacturing
- Industry
- Electrical products
- Address
- Gongju-si South Korea
- IPO Date
- Nov 6, 2020
- Website
- solux.co.kr
- Similar Companies
- Business
- ARIBIO Holdings Inc., formerly known as Sorlux Co., Ltd., is a South Korea-based holding and operating enterprise engaged in the manufacturing of energy-efficient LED lighting systems and the clinical-stage research, development, and commercialization of biopharmaceuticals targeting neurodegenerative and central nervous system diseases. The company operates through two primary business divisions: Lighting Solutions and Biopharmaceuticals. Its lighting product portfolio encompasses residential indoor lighting fixtures, including downlights, flat panel luminaires, slimline ceiling lamps, line lighting, and magnetic track systems; commercial and architectural luminaires, including recessed troffers, high-bay office lights, and adjustable spotlights; outdoor and municipal infrastructure illumination, including LED streetlights, security lamps, tunnel luminaires, floodlights, and architectural landscape lighting; specialized industrial luminaires, including explosion-proof fixtures and cleanroom lighting; and intelligent smart lighting management systems equipped with IoT wireless sensors and automated energy-control modules. Through its biopharmaceutical division and affiliated operating entity AriBio Co., Ltd., the company develops a pipeline of orally administered small-molecule therapeutics, led by AR1001 (mirodenafil), an oral phosphodiesterase-5 (PDE5) inhibitor undergoing global Phase 3 clinical evaluation for early-stage Alzheimer's disease; AR1002, a multi-mechanism therapeutic candidate targeting tauopathies; AR1003, a combination therapy for mild cognitive impairment; AR1004, a neuroprotective compound for ocular diseases and glaucoma; AR1005, an investigational therapy for amyotrophic lateral sclerosis; functional dietary health supplements promoting cognitive and metabolic wellness; and bio-cosmeceutical skincare formulations. In recent major developments, the company executed a corporate transformation and rebranding to ARIBIO Holdings Inc. following a change in control led by AriBio management, positioning the enterprise as an integrated biopharmaceutical platform. The company pursued a formal merger and operational consolidation with AriBio Co., Ltd. to streamline drug pipeline assets. Clinically, the company progressed its pivotal global Phase 3 POLARIS-AD trial for AR1001 across clinical sites in the United States, Europe, China, and South Korea, completing key treatment milestones. To support commercial rollout, the company entered into exclusive global and regional licensing partnerships for AR1001, including agreements with Shanghai Fosun Pharmaceutical for Greater China and selected international markets, as well as Samjin Pharm for the South Korean territory. Additionally, the company expanded its strategic life sciences portfolio through corporate equity transactions, including securing managerial stakes in biotechnology firms such as Cha Vaccine Institute. Founded in 1996, ARIBIO Holdings Inc. is headquartered in Gongju, South Korea, maintaining manufacturing facilities, research and development centers, and clinical operations across South Korea, the United States, and Europe.